Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2023 09:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix’s Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation

ST. LOUIS, March 06, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast and...
February 13, 2023 09:15 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals and Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical Trial

COLUMBUS, Ohio, and SAN FRANCISCO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc. and Quantum Leap Healthcare Collaborative™ today announced that Sermonix’s investigational...
February 08, 2023 09:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix to Present Poster Comparing Lasofoxifene and Fulvestrant Effect on Vaginal Health at International Society for the Study of Women's Sexual Health Annual Meeting 2023

COLUMBUS, Ohio, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
December 19, 2022 09:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Shares Two Recently Presented Posters Evaluating ESR1 Mutations in Circulating Tumor DNA From Patients With ER+/HER2- Metastatic Breast Cancer Who Were Treated With Lasofoxifene

Posters were presented Dec. 9 at the San Antonio Breast Cancer Symposium (SABCS)One abstract addressed patients who participated in the randomized Phase 2 ELAINE 1 study that assessed investigational...
December 09, 2022 08:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Shares Two Posters at SABCS 2022 on ER+/HER2- Metastatic Breast Cancer Patient Survey About Knowledge of NGS and ESR1 Mutations, Quality of Life Concerns

SAN ANTONIO, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically treat...
December 08, 2022 12:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge Into Practice

COLUMBUS, Ohio, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
November 17, 2022 09:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals Announces Four Abstracts Accepted for Presentation at 2022 San Antonio Breast Cancer Symposium

COLUMBUS, Ohio, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically treat...
October 21, 2022 10:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals Shares Additional Findings From Its ELAINE 1 Clinical Study at the 4th Annual Congress of the International Society of Liquid Biopsy

COLUMBUS, Ohio, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
September 14, 2022 11:22 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Based Regimen

Presentation delivered at the ninth-annual Metastatic Breast Cancer Research Conference in Park City, Utah Case was reported during Phase 2 study investigating efficacy of lasofoxifene, Sermonix’s...
September 13, 2022 09:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant in Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation

COLUMBUS, Ohio, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...